163 related articles for article (PubMed ID: 29423093)
1. Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells.
Valdez BC; Li Y; Murray D; Liu Y; Nieto Y; Champlin RE; Andersson BS
Oncotarget; 2018 Jan; 9(3):3908-3921. PubMed ID: 29423093
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin.
Robert C; Nagaria PK; Pawar N; Adewuyi A; Gojo I; Meyers DJ; Cole PA; Rassool FV
Leuk Res; 2016 Jun; 45():14-23. PubMed ID: 27064363
[TBL] [Abstract][Full Text] [Related]
3. Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy.
Valdez BC; Tsimberidou AM; Yuan B; Nieto Y; Baysal MA; Chakraborty A; Andersen CR; Andersson BS
Oncotarget; 2024 Jun; 15():361-373. PubMed ID: 38829622
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells.
Valdez BC; Tang X; Li Y; Murray D; Liu Y; Popat U; Champlin RE; Andersson BS
Exp Hematol; 2018 Nov; 67():49-59.e1. PubMed ID: 30102945
[TBL] [Abstract][Full Text] [Related]
5. HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs.
Valdez BC; Nieto Y; Yuan B; Murray D; Andersson BS
Oncotarget; 2022 Oct; 13():1122-1135. PubMed ID: 36243940
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.
Valdez BC; Li Y; Murray D; Ji J; Liu Y; Popat U; Champlin RE; Andersson BS
Exp Hematol; 2015 Jun; 43(6):448-61.e2. PubMed ID: 25704054
[TBL] [Abstract][Full Text] [Related]
8. Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells.
Valdez BC; Yuan B; Murray D; Nieto Y; Popat U; Andersson BS
Leuk Lymphoma; 2022 Jul; 63(7):1634-1644. PubMed ID: 35188042
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-Ribose) Polymerase Inhibitors for Arsenic Trioxide-Resistant Acute Promyelocytic Leukemia: Synergistic In Vitro Antitumor Effects with Hypomethylating Agents or High-Dose Vitamin C.
Giansanti M; De Gabrieli A; Prete SP; Ottone T; Divona MD; Karimi T; Ciccarone F; Voso MT; Graziani G; Faraoni I
J Pharmacol Exp Ther; 2021 Jun; 377(3):385-397. PubMed ID: 33820831
[TBL] [Abstract][Full Text] [Related]
10. The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.
Valdez BC; Li Y; Murray D; Liu Y; Nieto Y; Champlin RE; Andersson BS
Leuk Lymphoma; 2017 Nov; 58(11):2705-2716. PubMed ID: 28394191
[TBL] [Abstract][Full Text] [Related]
11. Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways.
Ghosh R; Roy S; Kamyab J; Danzter F; Franco S
DNA Repair (Amst); 2016 Sep; 45():56-62. PubMed ID: 27373144
[TBL] [Abstract][Full Text] [Related]
12. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
Chao OS; Goodman OB
Mol Cancer Res; 2014 Dec; 12(12):1755-66. PubMed ID: 25127709
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
[TBL] [Abstract][Full Text] [Related]
14. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK
Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625
[TBL] [Abstract][Full Text] [Related]
15. Synergistic cytotoxicity of fludarabine, clofarabine, busulfan, vorinostat and olaparib in AML cells.
Valdez BC; Yuan B; Murray D; Ramdial JL; Nieto Y; Popat U; Tang X; Andersson BS
Front Oncol; 2023; 13():1287444. PubMed ID: 38074694
[TBL] [Abstract][Full Text] [Related]
16. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells.
Valdez BC; Brammer JE; Li Y; Murray D; Teo EC; Liu Y; Hosing C; Nieto Y; Champlin RE; Andersson BS
Leuk Res; 2016 Aug; 47():100-8. PubMed ID: 27294334
[TBL] [Abstract][Full Text] [Related]
17. PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword.
Csizmar CM; Saliba AN; Swisher EM; Kaufmann SH
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34945003
[TBL] [Abstract][Full Text] [Related]
18. PARP-1 inhibition induces a late increase in the level of reactive oxygen species in cells after ionizing radiation.
Cieślar-Pobuda A; Saenko Y; Rzeszowska-Wolny J
Mutat Res; 2012 Apr; 732(1-2):9-15. PubMed ID: 22321899
[TBL] [Abstract][Full Text] [Related]
19. A combination of low-dose decitabine and chidamide resulted in synergistic effects on the proliferation and apoptosis of human myeloid leukemia cell lines.
Xu F; Guo H; Shi M; Liu S; Wei M; Sun K; Chen Y
Am J Transl Res; 2019; 11(12):7644-7655. PubMed ID: 31934307
[TBL] [Abstract][Full Text] [Related]
20. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
